Cyclacel Pharmaceuticals, Inc. financial data

Symbol
CYCC, CYCCP on Nasdaq
Industry
Pharmaceutical Preparations
Location
200 Connell Drive, Suite 1500, Berkeley Heights, New Jersey
State of incorporation
Delaware
Fiscal year end
December 31
Former names
XCYTE THERAPIES INC (to 3/24/2006)
Latest financial report
10-Q - Q1 2024 - May 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 123 % -70.8%
Debt-to-equity 338 % +963%
Return On Equity -841 % -621%
Return On Assets -177 % -129%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.32 M shares -89.5%
Common Stock, Shares, Outstanding 1.32 M shares -89.5%
Entity Public Float 5.62 M USD -51%
Common Stock, Value, Issued 1 K USD -88.9%
Weighted Average Number of Shares Outstanding, Basic 12.6 M shares +23.8%
Weighted Average Number of Shares Outstanding, Diluted 12.6 M shares +23.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 16.3 M USD -22.4%
Operating Income (Loss) -22.5 M USD +20.9%
Nonoperating Income (Expense) -238 K USD -138%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -22.7 M USD +18.2%
Income Tax Expense (Benefit) -3.03 M USD +38.2%
Net Income (Loss) Attributable to Parent -19.7 M USD +14%
Earnings Per Share, Basic -1.93 USD/shares -1.05%
Earnings Per Share, Diluted -2.27 USD/shares +67.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.8 M USD -75.5%
Other Assets, Current 365 K USD -38.7%
Assets, Current 4.84 M USD -74.5%
Property, Plant and Equipment, Net 7 K USD -77.4%
Operating Lease, Right-of-Use Asset 79 K USD -43.2%
Assets 6.17 M USD -72.7%
Accounts Payable, Current 5.2 M USD +107%
Accrued Liabilities, Current 3.15 M USD -36.3%
Liabilities, Current 8.35 M USD +12%
Operating Lease, Liability, Noncurrent 21 K USD -73.8%
Liabilities 8.37 M USD +11.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -898 K USD +26.6%
Retained Earnings (Accumulated Deficit) -431 M USD -4.79%
Stockholders' Equity Attributable to Parent -2.21 M USD -121%
Liabilities and Equity 6.17 M USD -72.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -483 K USD +93%
Net Cash Provided by (Used in) Financing Activities -79 K USD -58%
Net Cash Provided by (Used in) Investing Activities -6 K USD -50%
Common Stock, Shares Authorized 100 M shares 0%
Common Stock, Shares, Issued 1.32 M shares -89.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -580 K USD +91.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.8 M USD -75.5%
Deferred Tax Assets, Valuation Allowance 57.3 M USD +7.54%
Deferred Tax Assets, Gross 57.3 M USD +7.54%
Operating Lease, Liability 79 K USD
Depreciation 2 K USD -75%
Payments to Acquire Property, Plant, and Equipment 6 K USD +50%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -19.4 M USD +16.8%
Lessee, Operating Lease, Liability, to be Paid 87 K USD -46%
Property, Plant and Equipment, Gross 429 K USD +3.37%
Lessee, Operating Lease, Liability, to be Paid, Year Two 38 K USD -41.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 38 K USD -42.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8 K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 38 K USD
Deferred Tax Assets, Operating Loss Carryforwards 57.1 M USD +7.5%
Preferred Stock, Shares Authorized 5 M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Operating Lease, Payments 19 K USD +7.96%
Additional Paid in Capital 430 M USD +1.56%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 1.28 M USD -16.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%